Method and sources: Pricing and program terms were checked July 9, 2026 using Willow's program page, semaglutide page, tirzepatide page, FAQ, terms, and informed consent
[2] This consistent presence means the medication continuously influences how the body responds to carbohydrate intake, regardless of when meals are consumed
10.3 Pancreatitis & retinopathy risk Reports of pancreatitis and gastrointestinal intolerance, though infrequent, remain notable in real-world settings
That figure is not unique to GLP-1 medications, some lean tissue loss accompanies most significant weight loss, but the pace and scale of GLP-1-driven weight loss makes the risk more acute
Health Canada has approved a GLP-1 pill for the first time